Clinical Study on the Safety and Efficacy of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors
Latest Information Update: 04 Feb 2021
Price :
$35 *
At a glance
- Drugs Dendritic cells (Primary) ; Natural killer cell therapy (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Allife Medical Science and Technology
- 13 Mar 2020 New trial record